Maverick Therapeutics Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2017 | $56 M | No. 1 | $50 to $250 million | equity, options | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Maverick Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).
SEC Form D · Jan 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2017
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Maverick Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Hans Peter Gerber | Executive officer | Jan 2017 |
| Bard Geesaman | Director | Jan 2017 |
| Christopher Arendt | Director | Jan 2017 |
| Dan Hicklin | Director | Jan 2017 |
| Hans Peter Gerber | Director | Jan 2017 |
| Lori Kunkel | Director | Jan 2017 |
| Luke Evnin | Director | Jan 2017 |